Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus

Kim, Yoo Mee; Soo, Bong; Kim, Dae Jung; Choi, Sung Hee; Kim, Soo‐Kyung; Ahn, Chul Woo; Lim, Sung Kil; Kim, Kyung Rae; Huh, Kap Bum; Lee, Hyun Chul

doi:10.1016/j.diabres.2004.05.001

Cited by 33 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though marginal, there is a higher prevalence of T2D in young men than women (Wild, Roglic et al 2004, Ding, Song et al 2006), likely attributed to the fact that males are more susceptible to insulin resistance than females (van Genugten, Utzschneider et al 2006). Studies have also demonstrated that (i) the insulin analogue glargine causes a significantly greater decrease in HbA1c in males than females (Osterbrand, Fahlen et al 2007) and that (ii) males respond better to sulfonylureas than females (Donnelly, Doney et al 2006), while (iii) females respond more favorably to rosiglitazone than males (Kim, Cha et al 2005). Our understanding of sex dimorphisms in diabetes is compounded by underlying physiological differences which are numerous and include differences in glucose control and energy homeostasis (Basu, Dalla Man et al 2006), insulin disposal and clearance (Jensen, Nielsen et al 2012), regional fat disposition (Geer and Shen 2009, Macotela, Boucher et al 2009), and sex steroid hormones (Shi and Clegg 2009).…”

Section: Discussionmentioning

confidence: 99%

“…Current therapeutic options for DPN rely on controlling and treating T2D; however, significant gender dimorphisms in the responsiveness of patients to anti-diabetic drugs have been reported (Kim, Cha et al 2005, Donnelly, Doney et al 2006, Osterbrand, Fahlen et al 2007). These observations highlight the importance of elucidating gender-specific differences in diabetes disease manifestation; a decree which has been iterated by the National Institutes of Health (Clayton and Collins 2014).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gender-specific differences in diabetic neuropathy in BTBR ob/ob mice

O’Brien

Hur

Robell

et al. 2016

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

Aims To identify a female mouse model of diabetic peripheral neuropathy (DPN), we characterized DPN in female BTBR ob/ob mice and compared their phenotype to non-diabetic and gender-matched controls. We also identified dysregulated genes and pathways in sciatic nerve (SCN) and dorsal root ganglia (DRG) of female BTBR ob/ob mice to determine potential DPN mechanisms. Methods Terminal neuropathy phenotyping consisted of examining latency to heat stimuli, sciatic motor and sural sensory nerve conduction velocities (NCV), and intraepidermal nerve fiber (IENF) density. For gene expression profiling, DRG and SCN were dissected, RNA was isolated and processed using microarray technology and differentially expressed genes were identified. Results Similar motor and sensory NCV deficits were observed in male and female BTBR ob/ob mice at study termination; however, IENF density was greater in female ob/ob mice than their male counterparts. Male and female ob/ob mice exhibited similar weight gain, hyperglycemia, and hyperinsulinemia compared to non-diabetic controls, although triglycerides were elevated more so in males than in females. Transcriptional profiling of nerve tissue from female mice identified dysregulation of pathways related to inflammation. Conclusions Similar to males, female BTBR ob/ob mice display robust DPN, and pathways related to inflammation are dysregulated in peripheral nerve.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Gender-specific differences in diabetic neuropathy in BTBR ob/ob mice

O’Brien

Hur

Robell

et al. 2016

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

show abstract

“…In SU treated patients, a subgroup analyses of the ADOPT study [1], suggested that the treatment effect was significantly greater with rosiglitazone than with glyburide among obese patients (>30 kg/m 2 ) compared to overweight patients (≤30 kg/m 2 ). In metformin treated patients, a study in Korean T2DM patients [4] indicated that one of the predictors of good response to metformin or rosiglitazone was higher BMI. Moreover, as reported by Jones et al [18], the addition of rosiglitazone to metformin was most effective in obese, insulin-resistant patients with type 2 diabetes.…”

Section: Discussionmentioning

confidence: 99%

“…The post-hoc analysis of ADVANCE study [2,3] indicated that one of the independent predictors of change in HbA1c with gliclazide MR was baseline BMI (p < 0.001). In a group of Korean type 2 diabetes patients [4], one of the predictors of good response to metformin was higher BMI. In the same group of patients, they also found that the predictor of good response to rosiglitazone was higher BMI.…”

Section: Introductionmentioning

confidence: 99%

Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis

et al. 2016

View full text Add to dashboard Cite

AimThe aim of this study is to compare the effects of hypoglycemic treatments in groups of patients categorized according to the mean baseline body mass indexes (BMIs).MethodsStudies were identified by a literature search and all the studies were double blind, placebo-controlled randomized trials in type 2 diabetes patients; study length of ≥12 weeks with the efficacy evaluated by changes in HbA1c from baseline in groups. The electronic search was first conducted in January 2015 and repeated in June 2015.Results227 studies were included. Treatment with sulfonylureas was compared with placebo in overweight patients and resulted in a significantly greater change in the HbA1c levels (weighted mean difference (WMD), −1.39%) compared to obese patients (WMD, −0.77%)(p<0.05). Treatment with metformin in overweight patients resulted in a comparable change in the HbA1c levels (WMD, −0.99%) compared to obese patients (WMD, −1.06%)(p>0.05). Treatment with alpha glucosidase inhibitors in normal weight patients was associated with a HbA1c change (WMD, −0.94%) that was comparable that in overweight (WMD, −0.72%) and obese patients (WMD, −0.56%)(p>0.05). Treatment with thiazolidinediones in normal weight patients was associated with a HbA1c change (WMD, −1.04%) that was comparable with that in overweight (WMD, −1.02%) and obese patients (WMD, −0.88%)(p>0.05). Treatment with DPP-4 inhibitors in normal weight patients was associated with a HbA1c change (WMD, −0.93%) that was comparable with that in overweight (WMD, −0.66%) and obese patients (WMD, −0.61%)(p>0.05). In total, of the seven hypoglycemic agents, regression analysis indicated that the mean baseline BMI was not associated with the mean HbA1c changes from baseline.ConclusionIn each kind of hypoglycemic therapy in type 2 diabetes, the baseline BMI was not associated with the efficacy of HbA1c changes from baseline.

show abstract

“…High fCP is associated with response to the thiazolidinediones, rosiglitazone and pioglitazone, which is in keeping with their action of reducing insulin resistance [44, 45]. Whilst cohort studies of mixed DPP4 inhibitor use has shown that initial higher fCP predicts reduction of HbA1c, this association was not found in a retrospective study of sitagliptin use in addition to metformin or a sulfonylurea [46–48].…”

Section: Prediction Of Response To Non-insulin Therapies In T2dmmentioning

confidence: 99%

A Practical Review of C-Peptide Testing in Diabetes

2017

View full text Add to dashboard Cite

C-peptide is a widely used measure of pancreatic beta cell function. It is produced in equimolar amounts to endogenous insulin but is excreted at a more constant rate over a longer time. Methods of estimation include urinary and unstimulated and stimulated serum sampling. Modern assays detect levels of c-peptide which can be used to guide diabetes diagnosis and management. We explore the evidence behind the various tests available. We recommend the glucagon stimulation c-peptide testing owing to its balance of sensitivity and practicality. C-peptide levels are associated with diabetes type and duration of disease. Specifically a c-peptide level of less than 0.2 nmol/l is associated with a diagnosis of type 1 diabetes mellitus (T1DM). C-peptide level may correlate with microvascular and macrovascular complications and future use of insulin therapy, as well as likely response to other individual therapies. We explore the potential uses of c-peptide measurement in clinical practice.

show abstract

Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus

Cited by 33 publications

References 34 publications

Gender-specific differences in diabetic neuropathy in BTBR ob/ob mice

Gender-specific differences in diabetic neuropathy in BTBR ob/ob mice

Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis

A Practical Review of C-Peptide Testing in Diabetes

Contact Info

Product

Resources

About